The effect of the modified Glasgow prognostic score in metastatic gastric cancer

Background: Metastatic gastric cancer (GC) is the third most common cause of cancer-related death. At the time of metastatic stage treatment is given for palliative purposes. Therefore parameters other than performance status are needed to determine the prognosis. Objectives: It is aimed demonstrate that the modified Glasgow Prognostic Score (mGPS) is prognostic factor for overall survival and mGPS is a sensitive marker in patients diagnosed with metastatic GC in Turkish population. Materials and Methods: Clinical and laboratory data were collected and evaluated in the form of retrospective file scanning of One hundred forty-five patients with metastatic GC in Private Izmir Kent Hospital between 2017 and 2022. Analyzed factors included age, gender, precense of de novo or recurrent disease, first line treatment, ECOG-PS score, mGPS, CRP, and albumin levels, Progression Free Survival (PFS) and Overal Survival (OS). Results: The median age at diagnosis was 67 years, the median progression-free survival (PFS) was 5.3 months, and the median overall survival (OS) was 9.5 months. OS was 15.1 months in patients with an mGPS of 0, 9.3 months in patients with an mGPS of 1, and 6.4 months in patients with an mGPS of 2 (*p=0.001). Conclusions: mGPS is an easy to use and applicable parameter in Metastatic GC. High mGPS is poor prognostic factor for both PFS and OS in metastatic GC

Comparing female-based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population

Aim: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is 10 times more prevalent in women, particularly those of reproductive age. The varying effects of pregnancy on SLE and the differences between available SLE treatments make pregnancy timing and contraceptive methods significant. We aimed to determine the contraceptive methods used by SLE patients in the north-west part of Turkey, and compared them with those used by rheumatoid arthritis (RA) patients and healthy controls

Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is the MONALEESA-7 study, and data on the effectiveness of palbociclib is limited. Data are also limited regarding the effectiveness of CDK 4-6 inhibitors in patients whose dose was reduced due to neutropenia, the most common side effect of CDK 4-6 inhibitors. In our study, we aimed to evaluate the effectiveness of palbociclib and ribociclib in first-line treatment in patients with premenopausal metastatic breast cancer and the effect of dose reduction due to neutropenia on progression-free survival. Our study is a multicenter, retrospective study, and factors affecting progression-free survival (PFS) were examined in patients diagnosed with metastatic premenopausal breast cancer from 29 different centers and receiving combination therapy containing palbociclib or ribociclib in the metastatic stage. 319 patients were included in the study. The mPFS for patients treated with palbociclib was 26.83 months, and for those receiving ribociclib, the mPFS was 29.86 months (p = 0.924). mPFS was 32.00 months in patients who received a reduced dose, and mPFS was 25.96 months in patients who could take the initial dose, and there was no statistical difference (p = 0.238). Liver metastasis, using a fulvestrant together with a CDK 4-6 inhibitor, ECOG PS 1 was found to be a negative prognostic factor. No new adverse events were observed. In our study, we found PFS over 27 months in patients diagnosed with premenopausal breast cancer with CDK 4-6 inhibitors used in first-line treatment, similar to post-menopausal patients. We did not detect any difference between the effectiveness of the two CDK 4-6 inhibitors, and we showed that there was no decrease in the effectiveness of the CDK 4-6 inhibitor in patients whose dose was reduced due to neutropenia